Matthew L. Posard, Director: Halozyme Therapeutics HALO Sell · Filed 10/02

Trade details

Type: Insider sale
Amount: $120,525.9
Shares · price: 1,100 sh · $109.57 a share
Held after: 53,709 sh
Stock: Halozyme Therapeutics HALO
Person: Matthew L. PosardDirector
Trade date: 26/10/01
Filed: 26/10/02
Days to filing: 1 days

Sold 2.0% of holdings

Share of holding sold: 2.0%

Halozyme Therapeutics trades, last 26 weeks

What else happened in Halozyme Therapeutics around then

Filed or reported within 30 days of the trade day · 09/01~10/31

Matthew L. Posard's recent trades

Matthew L. PosardDirector
Sell10b5-1 planHalozyme Therapeutics
Sell10b5-1 plan
Halozyme Therapeutics
HALO
$357.9K
3,300 sh
$357.9K
Filed 10/02
Traded 10/01
Matthew L. PosardDirector
Sell10b5-1 planHalozyme Therapeutics
Sell10b5-1 plan
Halozyme Therapeutics
HALO
$78.2K
730 sh
$78.2K
Filed 10/02
Traded 10/01
Matthew L. PosardDirector
Sell10b5-1 planHalozyme Therapeutics
Sell10b5-1 plan
Halozyme Therapeutics
HALO
$11K
100 sh
$11K
Filed 10/02
Traded 10/01
Matthew L. PosardDirector
Planned sale10b5-1 planHalozyme Therapeutics
Planned sale10b5-1 plan
Halozyme Therapeutics
HALO
$3.6M
34,226 sh
$3.6M
Filed 09/16
Traded 09/16
Matthew L. PosardDirector
SellHalozyme Therapeutics
Sell
Halozyme Therapeutics
HALO
$570.1K
9,881 sh
$570.1K
Filed 24/08/14
Traded 24/08/14